Victor M. Villalobos

Family Medicine

6151 Dew Dr Ste 410
El Paso, TX 79912

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Trends in Self-Reported Responses to Nutrition Facts Labels Before and After Nutrition Labeling Policy Implementation: A Comparison of Adults in the United States and Mexico.

Trends in Self-Reported Responses to Nutrition Facts Labels Before and After Nutrition Labeling Policy Implementation: A Comparison of Adults in the United States and Mexico.

Journal: Current developments in nutrition

Published: December 18, 2025

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2025

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas.

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas.

Journal: Cancers

Published: July 29, 2023

Corrigendum: Elena+ Care for COVID-19, a Pandemic Lifestyle Care Intervention: Intervention Design and Study Protocol.

Corrigendum: Elena+ Care for COVID-19, a Pandemic Lifestyle Care Intervention: Intervention Design and Study Protocol.

Journal: Frontiers in public health

Published: November 04, 2021

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 03, 2021

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 19, 2020

Elena+ Care for COVID-19, a Pandemic Lifestyle Care Intervention: Intervention Design and Study Protocol.

Elena+ Care for COVID-19, a Pandemic Lifestyle Care Intervention: Intervention Design and Study Protocol.

Journal: Frontiers in public health

Published: November 03, 2020

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.

Journal: Cancer chemotherapy and pharmacology

Published: September 08, 2020

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 21, 2020

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.

Journal: Cancer

Published: July 09, 2020

To drive or not to drive? A study of travel behavior for a recent drinking occasion.

To drive or not to drive? A study of travel behavior for a recent drinking occasion.

Journal: Travel behaviour & society

Published: July 01, 2020

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Journal: The Lancet. Oncology

Published: May 14, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026